CONNECT WITH US
HealthTech

HealthTech

Anthropic's Nathan Frey on biopharma partners, M&A and pipeline

Endpoints News logo

Published on

Add as a preferred source on Google
Anthropic's Nathan Frey on biopharma partners, M&A and pipeline

Anthropic's Nathan Frey, interviewed on stage at Endpoints AI day (Brian Benton Photography)

Q&A: An­throp­ic's drug R&D chief talks catch­ing Prof. Oak, the lim­its of Claude's taste and cures vs. QALYs

Nathan Frey has stayed busy since An­throp­ic ac­quired his biotech start­up Co­ef­fi­cient Bio this spring.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Live at 10:30 am: Is biotech’s fu­ture full of ze­ro-em­ploy­ee star­tups? October 30, 2026

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion October 29, 2026

Flag­ship Pi­o­neer­ing merges three of its com­pa­nies for AI drug dis­cov­ery October 29, 2026

Af­ter Be Bio shut­down, its CEO heads to Or­bis; Enan­ta's long­time chief Jay Lu­ly to re­tire

Sanofi has no plans for a 'ma­jor' over­haul as Dupix­en­t's patent cliff looms

Se­tara gets $90M to con­tin­ue rare dis­ease pipeline spun out of Jaz­z's Ac­tio deal



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.